|
|
 |
|
Viewing report
|
|
|
|
Dyslipidemia: Opportunities in Cardiovascular Risk Reduction
Biophoenix Limited, July 2008, Pages: 210
This report examines trends in the dyslipidemia market, which is poised for transformation with the advent of novel combination products and biopharmaceuticals. Cholesterol (LDL and HDL) and triglycerides need to be controlled in individuals at risk of developing new or worsening cardiovascular disease (primary and secondary prevention). Antidyslipidemics on the market include statins, ezetimibe, fibrates, niacin products, bile acid sequestrants, and prescription omega-3 products. Many clinical trials over the past 30 years or so have shown that treatment with these drugs substantially reduces cardiovascular risk. The report reviews current approaches to treatment, drugs on the market, marketing strategies, lessons learnt from landmark clinical trials, biomarkers, surrogates of atherosclerosis for drug development, and over 150 products in commercial development. It also derives market forecasts (2008-2012) and assesses market potential.
Why buy this report?
Buy this report to gain an insight into the performance of statins and other lipid-modulating drugs and commercial implications of post-marketing clinical trials such as:
1. asteroid and enhance
2. identify biomarkers and surrogates of atherosclerosis, their potential and limitations in drug development
3. obtain market forecasts for the dyslipidemia market to 2012 by major market segments and geographic areas
4. discover why much of the growth in the dyslipidemia market is forecast to come from non-statin segments, in particular niacins and fibrates
5. be alerted to opportunities presented by the growing challenges of mixed dyslipidemias and undertreated patient subpopulations
6. identify companies developing novel lipid-modulating drugs and the most promising classes of drugs under development
About the Authors:
Dr Sreten Bogdanovic is Managing Director of Biophoenix Limited. He holds a PhD in endocrinology from Imperial College, UK, and has worked as product manager for immunodiagnostics with the UK subsidiary of Boehringer Mannheim (now owned by Roche), and as an independent biomedical market analyst with Cistron, UK.
Dr Langlands is Research Director. She holds a PhD in biochemistry from the University of Glasgow, UK, and has worked as an immunologist, a project leader with a new biotechnology company based at Warwick University in the UK, and as a university lecturer.
Publisher Note:
Biophoenix have researched and written over 50 management reports for clients such as Frost & Sullivan, PJB, Drug and Market Development Inc and Business Insights/Datamonitor
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Pipeline Insight: Dyslipidemia - Pipeline Agents Unlikely To Rejuvenate The Market
Dyslipidemia: The Expanding Market for Statins and other Lipid Management Products
Pipeline Insight: Dyslipidemia - Shift from statins to add-ons
The Dyslipidemia Market: Can Growth Be Sustained as Statin Patents Expire?
Dyslipidemia - Statins Dominate Treatment Pathway - For Now
Competitor Analysis: HDL Raising Therapies
Practical Lipid Management: Concepts and Controversies
Stakeholder Insight: Dyslipidemia - Titration versus Combination Therapy
Drugs of Tomorrow 2001: Dyslipidemia - The Advent of Third Generation and Combination Statins
Forecast Insight: Dyslipidemia - Genericization and Negative Trial Data Drive Market Shrinking
Statin Adjunct Therapy - Zetia, Revenue Protection for Zocor?
Expanding a Brand: Statins and PPAR-Gamma Agonists to Treat Neurological Disease
|
|
|
|
